PCSK9i reduces plaque burden in coronary arteries

PCSKi reduces plaque burden in coronary arteries
3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
  • Overview

    ACC 2022 ACS patients frequently harbor vulnerable plaques in non-infarct related coronary arteries. The PACMAN AMI study investigated to which degree vulnerable plaques can regress and stabilize in patients receiving alirocumab on top of high-intensity statin.

  • Educational information

    This video was recorded at the Congress of the American College of Cardiology (ACC) 2022.

  • Faculty

    Prof. Lorenz Räber, MD, PhD is an Interventional Cardiologist and Professor of Interventional Cardiology at Bern University Hospital in Bern, Switzerland.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of the PACMAN AMI study

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free